# **Systematix**

# **Institutional Equities**

# **Consumer Staples**

**14 February 2025** 

# **3QFY25 RESULT REVIEW**

Industry

**FMCG & Paints** 

### Nifty v/s NSE FMCG Index



Source: Bloomberg, Systematix Institutional Research

#### Company recommendations

Companies	СМР	TP	Rating
Britannia	4,945	5,755	BUY
Colgate	2,492	2,835	HOLD
Dabur	520	595	HOLD
GCPL	1,116	1,330	BUY
HUL	2,330	2,645	HOLD
ITC	412	475	HOLD
Marico	625	785	BUY
Nestle	2,178	2,560	HOLD
Tata Consumer	1,011	1,220	BUY
CCL Products	596	710	HOLD
Prataap Snacks	1,058	955	HOLD
Dodla Dairy	1,008	1,545	BUY
Asian Paints	2,250	2,870	BUY
Berger Paints	487	625	BUY
Kansai Nerolac	238	340	BUY
Patanjali Foods	1,801	2,115	BUY

Source: Systematix Institutional Research

### Abhishek Mathur

abhishekmathur@systematixgroup.in +91 22 6704 8059

#### Rajat Parab

rajatparab@systematixgroup.in +91 22 6704 8084

#### Vijay Jangir

vijayjangir@systematixgroup.in +91 22 6704 8029

# A weak quarter; demand, margins likely pick up from 1H26

Subdued demand in 3Q25; better numbers hoped for in 1Q26: Consumer staples' companies delivered 3QFY25 revenue growth in mid-single digits (+5% YoY for our coverage) on low-single digit volume growth (c.+2% YoY), in yet another quarter of subdued consumption demand amid elevated food inflation and high competitive intensity. Rural/Tier 2-4 markets sustained their growth momentum while Metros/Tier-1/urban markets remained stressed, especially in general trade (GT) channel and largely among lower/lower-middle income (LMIG) consumers. Some downtrading to smaller packs/ economical brands was also seen, impacting mix and realizations.

In categories (Exhibit 1: Category Growth Heatmap), demand was strained in soaps, juices, paints, home insecticides, tea and skin care. Relatively better growth was seen in detergents, biscuits, noodles, edible oil, coffee, chocolates, spices and kitchen foods; oral care and hair care were moderate. Britannia and Marico outperformed with volume +6% YoY each and revenue +8%/+15% YoY respectively. Paints industry has been witnessing an unprecedented slowdown; volume growth languished at flat/low-single digits (except Berger Paints outperforming with 7.4% growth) and negative mix persisted leading to revenue decline of c.3% YoY for the top 5 listed players. However, negative pricing was lower as base-quarter price cuts phased out.

**Looking ahead,** most companies flagged sluggish demand extending into 4Q25 (partly influenced by price hikes), but some indicated that a recovery might initialize from 1Q26. Paint companies expect a pickup in volume/ value growth over 4Q25/1Q26 driven by weak base and improving pricing growth.

Further price hikes planned; to support margins but crimp volumes: Sharp inflation in agri-commodity costs - mainly palm oil, tea, coffee, cocoa, wheat, copra – drove calibrated price hikes/ grammage cuts in low-mid single digits (double digits in edible oils) by nearly all companies (price/mix c.+3.5% YoY in 3Q25), which likely limited volume growth. Further hikes are planned by many companies in 4Q25, mainly in soaps, tea, biscuits, edible oils, hair oils, coffee, chocolates, toothpastes and juices; these would improve realizations but also exert some pressure on volume growth.

Margins can pick up QoQ from here: Gross/ operating margins were meaningfully impacted in 3Q25 (GPM/OPM decline of 200/135bps YoY for our coverage – EBITDA/PAT declines of 1%/6% YoY) by (1) pricing actions materially lagging sharp raw material inflation, and (2) high brand/staff/distribution spends; OPMs were partly cushioned by cost-saving initiatives. HUL and Dabur outperformed with OPMs-15/-20bps YoY and EBITDA +2%/+1% YoY respectively. In paints, GPM/OPM declined 90/235bps YoY with EBITDA/PAT declines of 15-16% YoY; however, margins improved QoQ; Akzo Nobel and Berger Paints outperformed here. We expect staples' margins to improve QoQ from here, with (1) further price hikes and (2) volume growth pickup driving operating leverage. However, high brand/ salesforce/ reach/ trade spends would continue with no let-up in competitive intensity.

**Stock picks:** With valuations correcting materially over past 3 months (stock declines of 10-25%), we prefer stocks with (1) pricing power in key categories, (2) potential to gain market share from small/local players, and (3) relatively better growth tailwinds in operating segments. **We prefer Marico and GCPL in HPC, Britannia and Tata Consumer in foods, Berger Paints in paints and Dodla Dairy in small/ midcaps**.

**Exhibit 1: Category value growth Heatmap** 

Categories/ value growth YoY	1Q24	2Q24	3Q24	4Q24	1Q25	2Q25	3Q25
Paints	7.1%	1.2%	5.6%	0.6%	(0.9%)	(3.0%)	(3.0%)
Asian Paints	6.7%	0.2%	5.4%	-0.6%	-2.3%	-5.3%	-6.1%
Berger Paints	9.8%	3.6%	7.0%	3.1%	2.0%	0.3%	3.2%
Kansai Nerolac	5.1%	1.3%	5.0%	2.1%	-1.1%	-0.3%	0.2%
Akzo Nobel	6.6%	3.2%	4.7%	2.3%	3.7%	2.7%	1.7%
Soaps	1.0%	(0.5%)	(0.5%)	0.0%	(5.0%)	(5.0%)	(3.0%)
HUL Soaps	Low-single digit	Low-single digit volume growth	Impacted	Value decline	Mid/high-single digit decline	Value decline	Mid-single digit decline
GCPL soaps	Low-single digit	Flat growth	Mid-single digit volume growth	High-single digit volume growth	Low-single digit volume growth	Flat volume growth	Flat/low value decline
Jyothy personal care (soap, hand wash, toothpaste	21.1%	22.3%	22.3%	18.0%	10.9%	-4.5%	-3.7%
Detergents	12.0%	5.0%	2.0%	3.0%	5.0%	5.0%	7.0%
HUL fabric care	DD growth	Mid-single digit volume growth	Mid-single digit volume growth	Mid-single digit volume growth	High-single digit volume growth	High-single digit volume growth	High-single digit volume growth
Jyothy fabric care	18.1%	10.6%	11.9%	10.0%	8.8%	0.1%	9.3%
GCPL liquid detergents			Strong DD volume growth	Strong DD volume growth	Strong DD volume growth	Strong DD volume growth	Strong DD volume growth
Biscuits	9.5%	1.5%	2.5%	3.5%	4.0%	4.5%	7.0%
Britannia overall	9.0%	1.0%	2.0%	3.0%	4.0%	4.5%	6.5%
ITC Sunfeast	Strong growth	Resilient performance	Resilient performance	Resilient performance	Resilient performance	Resilient performance	High competitive intensity
Bector Foods	25.3%	25.7%	22.4%	18.2%	22.4%	23.6%	15.0%
Noodles	12.0%	8.0%	7.0%	9.0%	4.0%	2.0%	6.0%
Nestle noodles	DD growth	Growth momentum continued	Growth momentum continued	Strong growth	Continued growth momentum	Positive volume growth over last 9 months	High-single digit growth
ITC Yippee	Robust performance	Sustained no.2 amid high competition	Sustained no.2 amid high competition	Strengthening position	Sustained no.2 amid high competition	Sustained no.2 amid high competition	Sustained no.2 amid high competition
Edible oil	(14.0%)	(15.0%)	(20.0%)	(7.0%)	5.0%	12.0%	30.0%
Adani Wilmar edible oil	-14.0%	-19.0%	-23.0%	-5.5%	8.0%	21.0%	38.0%
Marico Saffola edible oil	-20.0%	-12.0%	-26.0%	-16.0%	-1.0%	2.0%	24.0%
Patanjali edible oil	-12.9%	-13.4%	-15.3%	-8.9%	-9.5%	9.6%	22.5%
Tea	1.0%	3.0%	2.0%	3.0%	0.0%	3.0%	5.0%
HUL Tea	Muted growth	Muted growth	Muted growth	Strengthened mkt leadership	Flat/low-single digit growth	High-single digit growth	Low-single digit growth
Tata Consumer tea	2.0%	5.0%	4.0%	2.0%	-1.0%	-3.0%	9.0%
Coffee	8.0%	9.0%	10.0%	11.0%	10.5%	12.0%	10.0%
Nestle coffee	Robust DD growth	Strong growth	Strong DD growth	Strong DD growth	DD growth	High DD growth	Robust growth
HUL Coffee	Mid-single digit growth	DD growth	DD growth	DD growth	DD growth	DD growth	DD growth
Juices & nectars - Dabur	(2.0%)	(10.0%)	6.9%	(1.5%)	2.8%	(11.6%)	(10.3%)
Chocolate confectionery - Nestle	10.0%	7.0%	4.5%	6.0%	5.0%	5.0%	7.0%
Aerated drinks - Varun Beverages	13.6%	21.2%	21.0%	11.3%	28.7%	24.1%	38.3%

Spices							
Dabur Badshah spices	24.0%	16.4%	33.0%	20.0%	15.0%	15.0%	15.5%
ITC Sunrise spices		Robust growth	Robust growth	Strengthening position	Robust growth	Strong growth	Strong growth
Kitchen foods	40.0%	40.0%	30.0%	30.0%	30.0%	25.0%	28.0%
Tata Consumer Sampann foods	51.0%	47.0%	40.0%	42.0%	37.0%	26.0%	23.0%
Marico foods	24.0%	25.0%	18.0%	24.0%	37.0%	28.0%	31.0%
Dabur foods (chutneys, pastes, dressings)	35.0%	40.4%	22.0%	20.7%	21.3%	20.6%	30.0%
Oral care	12.0%	5.5%	7.5%	11.0%	10.5%	8.0%	5.0%
Colgate overall	10.8%	6.1%	8.3%	10.4%	13.1%	10.0%	4.7%
HUL Oral Care	High DD growth	Mid-single digit growth	Mid-single digit growth	DD growth	Mid-single digit growth	High-single digit growth	Mid-single digit growth
Dabur oral care	13.0%	4.1%	8.1%	22.0%	11.4%	5.3%	9.1%
Hair care	5.0%	4.0%	4.0%	2.0%	4.0%	5.0%	5.0%
HUL Hair Care	Mid-single digit growth	High-single digit growth	DD growth	High-single digit growth	High-single digit growth	High-single digit growth	Mid-single digit volume growth
Dabur hair oils	10.0%	4.0%	4.5%	-2.5%	3.3%	3.8%	2.7%
Dabur shampoo	9.0%	4.1%	11.3%	6.1%	13.7%	3.2%	2.7%
Marico Parachute	-5.0%	-1.0%	0.0%	2.0%	6.0%	10.0%	15.0%
Marico VAHO	0.0%	1.0%	3.0%	-7.0%	-5.0%	-8.0%	-2.0%
Bajaj Consumer	6.5%	0.5%	3.3%	-4.6%	-8.8%	-1.4%	
Emami hair oils (Kesh King)	2.0%	-5.0%	-13.0%	-9.0%	-15.0%	-9.0%	-10.0%
Skin care	9.0%	9.0%	0.0%	0.5%	2.0%	3.0%	3.0%
HUL Skin Care	DD growth	DD growth	Slightly impacted	Low-single digit growth	Flat/low-single digit growth	Mid-single digit growth	Muted performance
Dabur skin care	3.5%	5.0%	4.5%	0.6%	6.1%	0.0%	5.6%
Emami skin care Boro Plus	19.0%	-4.0%	-9.0%	33.0%	4.0%	2.0%	20.0%
Healthcare	10.5%	5.0%	1.5%	5.0%	9.0%	6.0%	5.0%
Emami healthcare	11.0%	4.0%	0.0%	10.0%	11.0%	11.0%	13.0%
Dabur healthcare	10.0%	5.4%	3.0%	-1.5%	7.0%	4.0%	-1.3%
Cigarettes	11.0%	8.0%	5.0%	12.0%	7.0%	10.0%	12.0%
ITC cigarettes	10.9%	8.5%	2.3%	7.0%	6.1%	7.3%	8.1%
Godfrey Phillips	28.7%	14.9%	40.2%	21.0%	14.8%	28.9%	38.7%
VST Industries	10.9%	1.4%	7.7%	24.4%	-3.8%	3.1%	1.3%

More than 5% decline	
5% decline to 0%	
0% to 5% growth	
5% to 10%	
More than 10% growth	

Exhibit 2: Consumer staples (Rs mn) - Quarterly results

Britannia Ind (Rs mn)	Q3FY25	Q3FY24	Q2FY25	YoY	QoQ	Key Highlights	
Revenue	45,926	42,563	46,676	7.9	-1.6	Volume +6%; BRIT to take price hikes of 2.5%/1.5% in 4Q25/1Q26 (2% in 3Q25)	
Gross Margin	38.7	43.9	41.5	-515	-280	Decline due to sharply higher RM inflation not mitigated by price hikes (effective RM inflation 11%)	
EBITDA	7,699	8,211	8,334	-6.2	-7.6		
EBITDA Margin	16.8	19.3	17.9	-253	-109	Cost-savings programs expected to yield 2.5% to margins	
Adj PAT	5,067	5,593	5,816	-9.4	-12.9	RTM 2.0/ direct reach initiatives, distribution-led/brand-led strategy in focus states, aggression in premium launches, adjacencies expected to drive topline growth; margins to improve QoQ	
CCL Products Ltd	Q3FY25	Q3FY24	Q2FY25	YoY	QoQ	Key Highlights	
Revenue	7,584	6,645	7,382	14.1	2.7	Volume growth 3-4%; Long-term/ near-term guidance of 15%/ 10-20%	
Gross Margin	40.1	41.2	39.8	-104	37	India business grew 23% & Vietnam grew 6% YoY	
EBITDA	1,244	1,109	1,371	12.2	-9.2	Clients remain unwilling to commit to long-term contracts	
EBITDA Margin	16.4	16.7	18.6	-29	-216	Margin contraction due to lag in coffee pricing elevated cost-inflation	
Adj PAT	630	633	740	-0.4	-14.8	PAT growth partly impacted by higher interest cost and tax rate	
Colgate Palmolive India	Q3FY25	Q3FY24	Q2FY25	YoY	QoQ	Key Highlights	
Revenue						Mid-single digit volume growth (our est. +4.5% YoY) in	
	14,618	13,957	16,191	4.7	-9.7	toothpaste; soft demand in urban mkts; premium growing 3x of portfolio	
Gross Margin	14,618 69.9	72.2	16,191	-226	-9.7 137		
	,	,	·			growing 3x of portfolio  Compression due lower realizations with aggressive	
Gross Margin	69.9	72.2	68.5	-226	137	growing 3x of portfolio  Compression due lower realizations with aggressive	
Gross Margin EBITDA	69.9	72.2	68.5 4,974	-226 -3.0	137 -8.6	growing 3x of portfolio  Compression due lower realizations with aggressive trade/ consumer promotions  Compression due to sustained high A&P spend (14% of sales) & reach expansion; OPMs to remain meaningfully	
Gross Margin  EBITDA  EBITDA Margin	69.9 4,544 31.1	72.2 4,684 33.6	68.5 4,974 30.7	-226 -3.0 -248	-8.6 36	growing 3x of portfolio  Compression due lower realizations with aggressive trade/ consumer promotions  Compression due to sustained high A&P spend (14% of sales) & reach expansion; OPMs to remain meaningfully pressured near-term  Near-term volume growth moderation with realizations	
Gross Margin EBITDA EBITDA Margin Adj PAT	69.9 4,544 31.1 3,228	72.2 4,684 33.6 3,301	68.5 4,974 30.7 3,386	-226 -3.0 -248 -2.2	137 -8.6 36 -4.7	growing 3x of portfolio  Compression due lower realizations with aggressive trade/ consumer promotions  Compression due to sustained high A&P spend (14% of sales) & reach expansion; OPMs to remain meaningfully pressured near-term  Near-term volume growth moderation with realizations pressured; premium launches to drive better mix	
Gross Margin EBITDA EBITDA Margin Adj PAT Dabur India	69.9 4,544 31.1 3,228 <b>Q3FY25</b>	72.2 4,684 33.6 3,301 Q3FY24	68.5 4,974 30.7 3,386 <b>Q2FY25</b>	-226 -3.0 -248 -2.2 <b>YoY</b>	137 -8.6 36 -4.7 <b>QoQ</b>	growing 3x of portfolio  Compression due lower realizations with aggressive trade/ consumer promotions  Compression due to sustained high A&P spend (14% of sales) & reach expansion; OPMs to remain meaningfully pressured near-term  Near-term volume growth moderation with realizations pressured; premium launches to drive better mix  Key Highlights  India volume/ value growth +1%/ +2%; int'l rebounded to 8.5%; value growth expected in mid/mid-high single	
Gross Margin  EBITDA  EBITDA Margin  Adj PAT  Dabur India  Revenue	69.9 4,544 31.1 3,228 Q3FY25 33,553	72.2 4,684 33.6 3,301 <b>Q3FY24</b> 32,551	68.5 4,974 30.7 3,386 <b>Q2FY25</b> 30,286	-226 -3.0 -248 -2.2 <b>YoY</b> 3.1	137 -8.6 36 -4.7 <b>QoQ</b> 10.8	growing 3x of portfolio  Compression due lower realizations with aggressive trade/ consumer promotions  Compression due to sustained high A&P spend (14% of sales) & reach expansion; OPMs to remain meaningfully pressured near-term  Near-term volume growth moderation with realizations pressured; premium launches to drive better mix  Key Highlights  India volume/ value growth +1%/ +2%; int'l rebounded to 8.5%; value growth expected in mid/mid-high single digits in 4Q25/ FY26  HPC performed well with 6% YoY sales' growth, Healthcare muted at -1% YoY, F&B declined 6% YoY  Dabur to take further price hikes mainly in premium toothpastes and juices	
Gross Margin  EBITDA  EBITDA Margin  Adj PAT  Dabur India  Revenue  Gross Margin	69.9 4,544 31.1 3,228 <b>Q3FY25</b> 33,553	72.2 4,684 33.6 3,301 <b>Q3FY24</b> 32,551 48.6	68.5 4,974 30.7 3,386 <b>Q2FY25</b> 30,286 49.3	-226 -3.0 -248 -2.2 <b>YoY</b> 3.1	137 -8.6 36 -4.7 QoQ 10.8	growing 3x of portfolio  Compression due lower realizations with aggressive trade/ consumer promotions  Compression due to sustained high A&P spend (14% of sales) & reach expansion; OPMs to remain meaningfully pressured near-term  Near-term volume growth moderation with realizations pressured; premium launches to drive better mix  Key Highlights  India volume/ value growth +1%/ +2%; int'l rebounded to 8.5%; value growth expected in mid/mid-high single digits in 4Q25/ FY26  HPC performed well with 6% YoY sales' growth, Healthcare muted at -1% YoY, F&B declined 6% YoY  Dabur to take further price hikes mainly in premium	

Godrej Consumer Products	Q3FY25	Q3FY24	Q2FY25	YoY	QoQ	Key Highlights
Revenue	37,684	36,596	36,663	3.0	2.8	India volume/value flat/+3% YoY; Indonesia strong volumes/ value growth of 6%/9% YoY; GAUM sales weak (-16% YoY)
Gross Margin	54.1	55.9	55.6	-175	-145	Soft demand in HI, soaps; price hikes taken in soaps slightly lagging cost-inflation
EBITDA	7,559	8,407	7,596	-10.1	-0.5	India biz. margin erosion, High RM inflation (mainly palm) not fully compensated by price hikes limited GPM gain
EBITDA Margin	20.1	23.0	20.7	-291	-66	Mgmt expects 4Q OPM similar to 3Q, expansion from 1Q26 onwards; FY26 India OPM guided at lower end of 24-26%
Adj PAT	5,041	5,880	4,971	-14.3	1.4	Growth headwinds in soaps, HI seem near-term; other India segments, Indonesia, GAUM margins growing well
Hindustan Unilever	Q3FY25	Q3FY24	Q2FY25	YoY	QoQ	Key Highlights
Revenue	1,54,080	1,51,880	1,55,080	1.4	-0.6	Flat volumes & negative product mix with higher sale of small packs. Mass skin care, soaps, nutrition drinks, tea dragged growth; laundry, hair care, oral care did better
Gross Margin	50.7	51.5	51.0	-83	-37	Home Care volume grew in high-single digits, Beauty declined in low single digits, Personal care declined in mid single digits and F&R saw mid single digit volume decline
EBITDA	35,700	35,400	36,470	0.8	-2.1	GPM contraction due to delayed price hikes in soaps & tea; HUL indicated further hikes will be taken
EBITDA Margin	23.2	23.3	23.5	-14	-35	OPM contraction moderated with rationalising A&P spends & cost savings
Adj PAT	24,920	25,490	26,280	-2.2	-5.2	Near-term demand moderation to persist. Gradual volume growth pickup expected over FY26-FY27E, margins to remain range bound
ІТС	Q3FY25	Q3FY24	Q2FY25	YoY	QoQ	Key Highlights
Revenue	1,70,528	1,56,957	1,86,491	8.6	-8.6	Cigarette volume/revenue/EBIT margin growth of 4%/8%/-210bps YoY; sharp cost escalation in leaf tobacco
Gross Margin	54.4	56.8	51.6	-237	284	FMCG grew 4% YoY led by growth in Atta, spices, snacks, dairy, premium personal wash, homecare and agarbatti; margins contracted due to raw material costs
EBITDA	58,284	57,394	61,233	1.6	-4.8	Agri biz sales rebounded to +10% YoY driven by leaf tobacco and value-added products. EBIT margin strong rebound +120bps YoY
EBITDA Margin	34.2	36.6	32.8	-239	134	Paperboards +3% YoY, impacted by low-priced Chinese & Indonesian supplies & soft domestic demand
Adj PAT	48,934	49,504	49,759	-1.2	-1.7	
Marico Ltd	Q3FY25	Q3FY24	Q2FY25	YoY	QoQ	Key Highlights
Revenue	27,940	24,220	26,640	15.4	4.9	Domestic volume/ international CC growth of 6%/16% YoY. Price hikes in Parachute, Saffola oils drove topline
Gross Margin	49.5	51.3	50.8	-178	-129	Parachute value +15%, Saffola oil +24%, VAHO -2%, foods +31%, premium personal care (PPC)/digital-first brands robust
EBITDA	5,330	5,130	5,220	3.9	2.1	GPM contraction due to realizatoins lagging input-cost inflation
EBITDA Margin	19.1	21.2	19.6	-210	-52	EBITDA margin contracted likely due to higher distribution costs (Project Setu) & A&P spend (+19% YoY)
Adj PAT	3,990	3,830	3,880	4.2	2.8	Mgmt expects double-digit revenue growth in FY25, maintaining stable OPM above 20%, double-digit CC growth in int'l

Nestle India	Q3FY25	Q3FY24	Q2FY25	YoY	QoQ	Key Highlights
Revenue	47,797	46,004	51,040	3.9	-6.4	Volumes +2% YoY (our est.) supported by Maggi noodles reverting to growth, while milks & nutrition likely soft
Gross Margin	56.4	58.6	56.6	-221	-24	Significant food inflation continues in coffee, cocoa, wheat, edible oils; further price hikes likely planned
EBITDA	10,849	10,951	11,677	-0.9	-7.1	Focus on core categories, product innovations, reach expansion
EBITDA Margin	22.7	23.8	22.9	-111	-18	EBITDA margin contraction likely on high A&P/brand-building spends, network expansion, product launch-related costs
Adj PAT	6,880	7,629	7,161	-9.8	-3.9	Mgmt sees demand heading into a better growth trajectory going forward, but price hikes impacting volume growth
Prataap Snacks	Q3FY25	Q3FY24	Q2FY25	YoY	QoQ	Key Highlights
Revenue	4,446	4,083	4,411	8.9	0.8	Volume growth c.+7% (our est.). Taking grammage cuts, adding new touchpoints, optimizing sales at existing touchpoints with range selling
Gross Margin	23.1	33.1	29.1	-1001	-601	Focusing on priority markets and opportunity markets, premium product launches, listing on e/q-commerce platforms
EBITDA	(54)	347	192	-115.6	-128.3	GPM contraction due to sharp palm oil inflation and potato inflation Palm oil.
EBITDA Margin	-1.2	8.5	4.3	-973	-556	Grammage reduction, recipe adjustments, process reengineering & trade margin optimization partially helped impact mitigation
Adj PAT	(36)	108	(5)	-133.3	693.2	Seeking to recover OPMs with cost optimization, SFA, trade margin rationalization; maintains double-digit OPM guidance in 1-1.5 yrs
Tata Consumer Products	Q3FY25	Q3FY24	Q2FY25	YoY	QoQ	Key Highlights
Revenue	44,436	38,039	42,145	16.8	5.4	India tea volume +7% YoY, foods' biz grew value +31% YoY, Sampann grew +23% YoY. Took calibrated price hikes in tea.
Gross Margin	41.1	43.8	43.6	-273	-253	Int'l bevs grew 8% YoY driven by UK tea while US Coffee & Canada tea sales grew 5% YoY each
EBITDA	5,647	5,724	6,263	-1.3	-9.8	Gross margin contracted entirely on the sharp tea cost escalation not mitigated by pricing
EBITDA Margin	12.7	15.0	14.9	-234	-215	Op margin incorporated expansion in int'l but decline in India margins due to the tea cost escalation
Adj PAT	2,850	3,704	3,176	-23.0	-10.2	Sampann expected to remain the key growth engine. High pricing power in tea favourable for TCPL
Dodla Dairy	Q3FY25	Q3FY24	Q2FY25	YoY	QoQ	Key Highlights
Revenue	9,012	7,468	9,976	20.7	-9.7	Revenue growth supported by strong performance from Africa (+114%), Orgafeed (+62%) and VAP (+51%) sales
Gross Margin	28.2	30.0	25.5	-183	276	Milk sales volumes grew 8% & procurement volumes were down 2% YoY (inventory drawdown)
EBITDA	959	828	963	15.8	-0.3	Gross margin contracted due to high procurement cost in Africa/Kenya, higher sales of butter and SMP (low margin)
EBITDA Margin	10.6	11.1	9.6	-45	100	EBITDA margin also contracted due to higher staff costs (+20% YoY) and other expenses (+9% YoY)
Adj PAT	636	413	634	53.8	0.3	Growth in Africa business, pick-up in prices, higher VAP sales and recent capacity expansions to aid growth

Asian Paints	Q3FY25	Q3FY24	Q2FY25	YoY	QoQ	Key Highlights
Revenue	85,494	91,031	80,275	-6.1	6.5	Sales impacted by subdued consumption demand (esp. urban), downtrading, weak festive season; Volume growth of +1.6%
Gross Margin	42.4	43.6	40.8	-116	167	GPM contraction due to weak volumes & price/mix remaining negative. Pricing should turn positive in 4Q25 with base-qtr cuts phasing out
EBITDA	16,367	20,561	12,395	-20.4	32.0	Op margin decline led by higher employee & other costs. OPMs recovered QoQ basis
EBITDA Margin	19.1	22.6	15.4	-344	370	
Adj PAT	11,105	14,477	8,748	-23.3	26.9	APNT aiming for low-single digit volume growth in 4Q25, but value growth could remain pressured
Berger Paints	Q3FY25	Q3FY24	Q2FY25	YoY	QoQ	Key Highlights
Revenue	29,751	28,818	27,746	3.2	7.2	Decorative volume +7.4% YoY (industry-leading); negative product mix
Gross Margin	41.6	41.1	41.7	54	-8	Volumes driven by distribution expansion, progress in urban expansion initiatives
EBITDA	4,717	4,800	4,342	-1.7	8.6	Gross margin expansion led by better volumes
EBITDA Margin	15.9	16.7	15.6	-80	21	OPM decline due to higher manpower recruitment for urban expansion, and some currency depreciation
Adj PAT	2,951	2,997	2,697	-1.5	9.4	BRGR expects double-digit volume growth in 4Q25 with mid-high single digit value growth; OPMs in 15-17% band
Kansai Nerolac	Q3FY25	Q3FY24	Q2FY25	YoY	QoQ	Key Highlights
Revenue	19,219	19,187	18,638	0.2	3.1	Subdued decorative demand (our est2.5% YoY), firm auto coatings' demand (our est. +5.5% YoY), strong non-auto industrial (our est. +8% YoY)
Gross Margin	35.2	36.1	34.0	-83	127	GM declined due to adverse segment mix (decorative growing slower vs industrial) and lagging pricing (vs RM inflation)
EBITDA	2,351	2,440	2,119	-3.7	10.9	
EBITDA Margin	12.2	12.7	11.4	-49	86	Decorative demand expected to pick up, auto/industrial growth to sustain, increasing salience of 'Paint+' premium products and B2B sales; OPM expected to remain in 13-14% guidance.
Adj PAT	1,739	1,543	1,358	12.7	28.0	
Patanjali Foods	Q3FY25	Q3FY24	Q2FY25	YoY	QoQ	Key Highlights
Revenue	91,031	79,107	81,542	15.1	11.6	Revenue growth driven by edible oil sales growth of 23% YoY, while foods sales declined 18% YoY
Gross Margin	15.8	12.7	15.3	313	52	Gross margins benefited from pass-through of oil cost inflation & raw material inventory gains
EBITDA	5,405	3,440	4,491	57.1	20.4	Edible oil margins expanded 340bps YoY, foods OPM declined 330bps YoY due to higher palm oil, wheat, A&P costs
EBITDA Margin	5.9	4.3	5.5	159	43	PFL expects pickup in edible oil volumes and foods/ghee sales, HPC to grow 10-12%; remains cautiously optimistic of demand recovery; plans to increase direct reach to 2mn near-term
Adj PAT	3,709	2,165	3,086	71.3	20.2	PFL expects edible oil margins to normalize to 4%-odd medium-term, food margins to improve to 8-10% going fwd, HPC margins to improve beyond 13.6% in 3Q25

Exhibit 3: YoY revenue growth in 3QFY25 for our coverage universe





Exhibit 4: YoY EBITDA growth in 3QFY25 for our coverage universe



Source: Systematix Institutional Research

Exhibit 5: YoY PAT growth in 3QFY25 for our coverage universe




Exhibit 6: Revised estimates – Upgrade / Downgrade

Consumer Staples	Upgrade/Downgrade	Upgrade/Downgrade	Upgrade/Downgrade		
Britannia Ind (Rs mn)	FY25E	FY26E	FY27E		
Revenue	0.2%	0.5%	0.7%		
EBITDA	-1.6%	0.2%	2.1%		
Adj PAT	-1.3%	0.4%	2.4%		
CCL Products Ltd	FY25E	FY26E	FY27E		
Revenue	-3.9%	-3.4%	-3.8%		
EBITDA	0.5%	0.9%	1.0%		
Adj PAT	3.0%	0.6%	-0.4%		
Colgate Palmolive India	FY25E	FY26E	FY27E		
Revenue	-1.7%	-1.7%	-1.7%		
EBITDA	-0.9%	0.4%	0.7%		
Adj PAT	-1.1%	0.2%	0.4%		
Dabur India	FY25E	FY26E	FY27E		
Revenue	-0.4%	-3.4%	-3.4%		
EBITDA	-0.8%	-5.4%	-6.5%		
Adj PAT	1.0%	-3.8%	-5.1%		
Godrej Consumer Products	FY25E	FY26E	FY27E		
Revenue	0.5%	0.4%	0.4%		
EBITDA	-1.0%	-1.2%	-0.8%		
Adj PAT	-2.8%	-2.2%	-1.2%		
Hindustan Unilever	FY25E	FY26E	FY27E		
Revenue	-1.1%	-1.1%	-1.1%		
BITDA	-0.7%	-0.7%	-0.7%		
Adj PAT	-1.3%	-1.2%	-1.1%		
тс	FY25E	FY26E	FY27E		
Revenue	-2.2%	-5.2%	-5.0%		
EBITDA	-2.7%	-6.1%	-6.5%		
Adj PAT	-4.9%	-7.7%	-8.0%		
Marico Ltd	FY25E	FY26E	FY27E		
Revenue	2.8%	2.9%	2.9%		
EBITDA	2.3%	3.3%	4.6%		
Adj PAT	4.4%	3.3%	4.6%		
Nestle India	FY25E	FY26E	FY27E		
Revenue	-0.7%	-0.8%	-1.0%		
EBITDA	-1.4%	-1.5%	-2.0%		
Adj PAT	-3.6%	-5.0%	-5.4%		
Prataap Snacks	FY25E	FY26E	FY27E		
Revenue	0.9%	0.9%	0.9%		
EBITDA	-51.1%	-5.4%	-3.0%		
Adj PAT	-102.8%	-8.8%	-3.1%		

Consumer Staples	Upgrade/Downgrade	Upgrade/Downgrade	Upgrade/Downgrade		
Tata Consumer Products	FY25E	FY26E	FY27E		
Revenue	0.0%	0.0%	0.0%		
EBITDA	-7.1%	-6.2%	-4.2%		
Adj PAT	-14.3%	-7.7%	-5.1%		
Dodla Dairy	FY25E	FY26E	FY27E		
Revenue	2.0%	2.0%	2.0%		
EBITDA	0.0%	2.0%	2.0%		
Adj PAT	3.0%	5.0%	5.0%		
Asian Paints	FY25E	FY26E	FY27E		
Revenue	-4.1%	-4.0%	-4.1%		
EBITDA	-8.0%	-5.6%	-2.1%		
Adj PAT	-9.4%	-6.3%	-2.5%		
Berger Paints	FY25E	FY26E	FY27E		
Revenue	-1.5%	-2.3%	-2.3%		
EBITDA	-2.0%	-2.7%	-2.7%		
Adj PAT	-4.3%	-5.2%	-5.2%		
Kansai Nerolac	FY25E	FY26E	FY27E		
Revenue	-2.6%	-2.6%	-2.6%		
EBITDA	-2.7%	-3.0%	-2.2%		
Adj PAT	-0.1%	-1.7%	-1.0%		
Patanjali Foods	FY25E	FY26E	FY27E		
Revenue	0.6%	0.2%	-0.2%		
EBITDA	-0.6%	-4.3%	-6.9%		
Adj PAT	2.3%	-2.5%	-5.5%		

**Exhibit 7: Valuation snapshot** 

	Consumer Staples									
			Target	Upside	Mkt.Cap	CAGR	over FY24-2	7E (%)	Valuation on FY27E	
Company	Rating	СМР	Price	(%)	(Rs bn)	Revenue	EBITDA	Adj. EPS	PE (x)	EV/ EBITDA (x)
Britannia Ind	BUY	4945	5,755	16	1191	9.0	8.4	9.4	42	29.9
CCL Products Ltd	HOLD	596	710	19	80	19.1	19.3	21.9	17	12.4
Colgate Palmolive India	HOLD	2492	2,835	14	678	9.6	9.3	9.6	38	26.8
Dabur India	HOLD	520	595	14	921	6.2	6.5	7.4	40	31.9
Godrej Consumer Products	BUY	1116	1330	19	1141	8.5	10.1	13.9	40	29.7
Hindustan Unilever	HOLD	2330	2,645	14	5476	6.6	8.1	8.2	42	29.2
ITC	HOLD	412	475	15	5155	8.7	6.9	5.3	21	15.8
Marico	BUY	625	785	26	809	11.0	11.9	13.1	38	28.3
Nestle India*	HOLD	2178	2,560	18	2100	9.3	10.4	8.9	51	33.0
Prataap snacks	HOLD	1058	955	-10	25	9.9	10.3	16.3	30	13.3
Tata Consumer Products	BUY	1011	1,220	21	1000	12.4	14.3	12.3	46	29.4
Dodla Dairy	BUY	1008	1,545	53	60	16.7	22.6	27.2	18	11.1
Asian Paints	BUY	2250	2,870	28	2158	5.9	1.9	0.4	40	26.5
Berger Paints	BUY	487	625	28	568	7.8	6.2	7.8	40	25.3
Kansai Nerolac	BUY	238	340	43	192	6.3	4.5	7.7	23	15.1
Patanjali Foods	BUY	1801	2,115	17	652	9.0	33.5	42.4	30	21.5

#### DISCLOSURES/APPENDIX

#### I. ANALYST CERTIFICATION

I, Abhishek Mathur, Rajat Parab, Vijay Jangir; hereby certify that (1) views expressed in this research report accurately reflect my/our personal views about any or all of the subject securities or issuers referred to in this research report, (2) no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report by Systematix Shares and Stocks (India) Limited (SSSIL) or its group/associate companies, (3) reasonable care is taken to achieve and maintain independence and objectivity in making any recommendations.

Disclosure of Interest Statement	Update
Analyst holding in the stock	No
Served as an officer, director or employee	No

- I. ISSUER SPECIFIC REGULATORY DISCLOSURES, unless specifically mentioned in point no. 9 below:
- 1. The research analyst(s), SSSIL, associates or relatives do not have any financial interest in the company(ies) covered in this report.
- 2. The research analyst(s), SSSIL, associates or relatives collectively do not hold more than 1% of the securities of the company(ies) covered in this report as of the end of the month immediately preceding the distribution of the research report.
- 3. The research analyst(s), SSSIL, associates or relatives did not have any other material conflict of interest at the time of publication of this research report.
- 4. The research analyst, SSSIL and its associates have not received compensation for investment banking or merchant banking or brokerage services or any other products or services from the company(ies) covered in this report in the past twelve months.
- 5. The research analyst, SSSIL or its associates have not managed or co-managed a private or public offering of securities for the company(ies) covered in this report in the previous twelve months.
- 6. SSSIL or its associates have not received compensation or other benefits from the company(ies) covered in this report or from any third party in connection with this research report.
- 7. The research analyst has not served as an officer, director or employee of the company(ies) covered in this research report.
- 8. The research analyst and SSSIL have not been engaged in market making activity for the company(ies) covered in this research report.
- 9. Details of SSSIL, research analyst and its associates pertaining to the companies covered in this research report:

Sr. No.	Particulars	Yes / No.
1	Whether compensation was received from the company(ies) covered in the research report in the past 12 months for investment banking transaction by SSSIL.	No
2	Whether research analyst, SSSIL or its associates and relatives collectively hold more than 1% of the company(ies) covered in the research report.	No
3	Whether compensation has been received by SSSIL or its associates from the company(ies) covered in the research report.	No
4	Whether SSSIL or its affiliates have managed or co-managed a private or public offering of securities for the company(ies) covered in the research report in the previous twelve months.	No
5	Whether research analyst, SSSIL or associates have received compensation for investment banking or merchant banking or brokerage services or any other products or services from the company(ies) covered in the research report in the last twelve months.	No

10. There is no material disciplinary action taken by any regulatory authority that impacts the equity research analysis activities.

#### STOCK RATINGS

BUY (B): The stock's total return is expected to exceed 15% over the next 12 months.

**HOLD (H):** The stock's total return is expected to be within -15% to +15% over the next 12 months.

SELL (S): The stock's total return is expected to give negative returns of more than 15% over the next 12 months.

 $\label{eq:NOT_RATED} \textbf{(NR):} \ \text{The analyst has no recommendation on the stock under review.}$ 

#### **INDUSTRY VIEWS**

ATTRACTIVE (AT): Fundamentals/valuations of the sector are expected to be attractive over the next 12-18 months.

NEUTRAL (NL): Fundamentals/valuations of the sector are expected to neither improve nor deteriorate over the next 12-18 months.

CAUTIOUS (CS): Fundamentals/valuations of the sector are expected to deteriorate over the next 12-18 months.

## II. DISCLAIMER

The information and opinions contained herein have been compiled or arrived at based on the information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy completeness or correctness.

This document is for information purposes only. This report is based on information that we consider reliable; we do not represent that it is accurate or complete and one should exercise due caution while acting on it. Description of any company(ies) or its/their securities mentioned herein are not complete and this document is not and should not be construed as an offer or solicitation of an offer to buy or sell any securities or other financial instruments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. All opinions, projections and estimates constitute the judgment of the author as on the date of the report and these, plus any other information contained in the report, are subject to change without notice. Prices and availability of financial instruments are also subject to change without notice. This report is intended for distribution to institutional investors.

This report is not directed to or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject to SSSIL or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently sent or has reached any individual in such country, especially USA, the same may be ignored and brought to the attention of the sender. Neither this document nor any copy of it may be taken or transmitted into the United States (to U.S. persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. Any unauthorized use, duplication, redistribution or disclosure of this report including, but not limited to, redistribution by electronic mail, posting of the report on a website or page, and/or providing to a third party a link,



is prohibited by law and will result in prosecution. The information contained in the report is intended solely for the recipient and may not be further distributed by the recipient to any third party.

SSSIL generally prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, SSSIL generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that they cover. Our salespeople, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein. Our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. The views expressed in this research report reflect the personal views of the analyst(s) about the subject securities or issues and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report. The compensation of the analyst who prepared this document is determined exclusively by SSSIL; however, compensation may relate to the revenues of the Systematix Group as a whole, of which investment banking, sales and trading are a part. Research analysts and sales persons of SSSIL may provide important inputs to its affiliated company(ies).

Foreign currencies denominated securities, wherever mentioned, are subject to exchange rate fluctuations which could have an adverse effect on their value or price or the income derived from them. In addition, investors in securities such as ADRs, the values of which are influenced by foreign currencies, effectively assume currency risk. SSSIL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on the basis of this report including but not restricted to fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

SSSIL and its affiliates, officers, directors, and employees subject to the information given in the disclosures may: (a) from time to time, have long or short positions in, and buy or sell, the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation (financial interest) or act as a market maker in the financial instruments of the company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) or have other potential material conflict of interest with respect to any recommendation and related information and opinions. The views expressed are those of the analyst and the company may or may not subscribe to the views expressed therein.

SSSIL, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall SSSIL, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. The company accepts no liability whatsoever for the actions of third parties. The report may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the report refers to website material of the company, the company has not reviewed the linked site. Accessing such website or following such link through the report or the website of the company shall be at your own risk and the company shall have no liability arising out of, or in connection with, any such referenced website.

SSSIL will not be liable for any delay or any other interruption which may occur in presenting the data due to any technical glitch to present the data. In no event shall SSSIL be liable for any damages, including without limitation, direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by SSSIL through this presentation.

SSSIL or any of its other group companies or associates will not be responsible for any decisions taken on the basis of this report. Investors are advised to consult their investment and tax consultants before taking any investment decisions based on this report.

Registration granted by SEBI to SSSIL and certification from NISM to the analyst in no way guarantee performance of SSSIL or to provide any assurance of returns to investors.





#### Systematix Shares and Stocks (India) Limited:

Registered and Corporate address: The Capital, A-wing, No. 603 – 606, 6th Floor, Plot No. C-70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051 Tel no. 022-66198000/40358000 Fax no. 022-66198029/40358029 Email id contactus@systematixgroup.in. Visit us at: www.systematixgroup.in Details of Compliance officer: Ms Nipa Savla, Compliance officer Tel no. 022-66198092/4035808092 Email id compliance@systematixgroup.in Details of Email id grievance redressal cell: grievance@systematixgroup.in

Details of Registration: CIN - U65993MH1995PLC268414 | BSE SEBI Reg. No.: INZ000171134 (Member Code: 182) | NSE SEBI Reg. No.: INZ000171134 (Member Code: 11327) | MCX SEBI Reg. No.: INZ000171134 (Member Code: 56625) | NCDEX SEBI Reg. No.: INZ000171134 (Member Code: 1281) | Depository Participant SEBI Reg. No.: IN-DP-480-2020 (DP Id: 12034600) | PMS SEBI Reg. No.: INP000002692 | Research Analyst SEBI Reg. No.: INH200000840 | AMFI: ARN - 64917

